Exploring the Impact of Metabolic Bariatric Surgery on Psoriasis Outcomes: Current Evidence and Insights

Psoriasis is a chronic, immune-mediated inflammatory condition affecting millions worldwide. Recent studies suggest that obesity may worsen psoriasis severity and complicate treatment outcomes. Interestingly, metabolic bariatric surgery (MBS), a widely used intervention for obesity, has been associated with improvements in psoriasis symptoms. This blog explores the latest evidence on psoriasis outcomes following MBS, highlighting the potential mechanisms, clinical results, and considerations for patients and healthcare providers.

Understanding Psoriasis and Its Link to Obesity

Psoriasis is a multisystem inflammatory disease with autoimmune origins. It affects around three percent of adults in the United States and is characterized by red, scaly skin lesions that often cause discomfort and stigma. Beyond the skin, psoriasis is associated with systemic comorbidities including cardiovascular disease, metabolic syndrome, hypertension, type 2 diabetes mellitus, and dyslipidemia.

A phenomenon known as the “psoriatic march” describes how persistent skin inflammation can lead to systemic inflammation, insulin resistance, and endothelial dysfunction. Obesity amplifies this inflammatory cascade, increasing the risk of comorbid conditions. Despite this established link, weight loss has not been emphasized enough in psoriasis management, even though evidence suggests that reducing excess weight may improve clinical outcomes and treatment response.

Metabolic Bariatric Surgery as a Potential Strategy

Metabolic bariatric surgery is a highly effective intervention for sustained weight loss and improvement of obesity-related metabolic conditions. Beyond reducing body weight, MBS induces hormonal changes, including elevated postprandial secretion of glucagon-like peptide-1 (GLP-1). GLP-1 has been linked to reductions in systemic inflammation and may play a role in improving psoriasis severity.

Several case reports and cohort studies have documented significant improvements in psoriasis following MBS. For example, the first reported case in 2004 described a patient achieving complete psoriasis remission for two years after laparoscopic Roux-en-Y gastric bypass. Since then, further research has explored the relationship between different bariatric procedures and psoriasis outcomes.

Review of Recent Evidence: Systematic Review Findings

A recent systematic review, published in BMC Surgery in 2026 by Kehagias et al., analyzed psoriasis outcomes in patients undergoing MBS. The review included six studies with a total of 447 patients, evaluating both clinical measures of psoriasis and treatment requirements.

Patient Demographics

Among the 159 patients with available demographic data, the mean age was 46.9 years, and the mean body mass index (BMI) was 43.8 kg/m². Approximately 74 percent were female. Comorbidities such as type 2 diabetes and hypertension were common, and roughly 24 percent had psoriatic arthritis. Procedures included Roux-en-Y gastric bypass (RYGBP), one-anastomosis gastric bypass (OAGB), sleeve gastrectomy (SG), and adjustable gastric banding (AGB).

Weight Loss Outcomes

Patients experienced significant weight reduction following MBS. Mean BMI decreased by approximately 11 kg/m², and total body weight loss was documented at 27.6 percent in one study. Additionally, comorbidity resolution rates were notable, with type 2 diabetes remission ranging from 61.5 to 75 percent and hypertension resolving in about 51 to 57 percent of cases. These outcomes reinforce the effectiveness of MBS for long-term metabolic improvement.

Psoriasis Outcomes

Psoriasis outcomes were assessed using the Psoriasis Area Severity Index (PASI), percentage of affected body surface area (%ABSA), nail involvement, and the Dermatology Life Quality Index (DLQI). Results from the review indicated significant improvements:

• DLQI decreased from 14.9 to 5.0, reflecting improved quality of life.
• %ABSA decreased from 5.7 to 1.7, indicating reduced skin involvement.
• PASI decreased from 3.6 to 1.2, showing lower disease severity.
• Nail involvement reduced from 43.8 percent to 21.9 percent.

Overall, 69.5 percent of patients experienced improvement or remission of psoriasis, defined primarily as a reduction or discontinuation of treatment. Systemic therapy use decreased from 53 to 34 percent, while topical therapy decreased slightly, and nearly 29 percent of patients required no treatment post-surgery.

Impact of Surgical Type

Subgroup analysis revealed that surgical technique influenced outcomes. Among patients undergoing gastric bypass procedures (RYGBP or OAGB), 80 percent showed improvement or remission. In contrast, only 10 percent of patients undergoing non-bypass procedures such as SG or AGB experienced similar outcomes. PASI reduction was also greater after bypass procedures. These findings suggest that gastric bypass may confer superior benefits for psoriasis, possibly due to more pronounced hormonal changes and weight loss.

Factors Associated with Improved Outcomes

The review identified several factors linked to better psoriasis outcomes after MBS:

• Greater excess weight loss (%EWL)
• Older age at the time of surgery
• Absence of a family history of psoriasis
• Undergoing Roux-en-Y gastric bypass
• Mild baseline psoriasis severity

These factors may help clinicians predict which patients are most likely to benefit from MBS beyond its primary effect on weight reduction.

Mechanisms of Psoriasis Improvement After Bariatric Surgery

The mechanisms underlying psoriasis improvement after MBS are not fully understood. Weight loss alone may reduce systemic inflammation and improve responsiveness to therapy. Additionally, hormonal changes following surgery, particularly increases in GLP-1, may exert immunomodulatory effects. GLP-1 receptor agonists have been shown in several studies to reduce PASI scores, suggesting that the same pathways activated by bariatric surgery could contribute to psoriasis improvement.

Furthermore, some patients experience psoriasis improvement before significant weight loss, supporting the hypothesis that hormonal and metabolic factors may play a crucial role alongside caloric restriction.

Clinical Implications

The findings from the systematic review provide several important clinical insights:

1. Psoriasis Improvement is Common: Nearly seven out of ten patients experienced improvement or remission following MBS.
2. Treatment Requirements May Decrease: Reduced reliance on systemic therapy and biologics may reduce treatment burden and associated side effects.
3. Surgical Type Matters: Gastric bypass procedures appear more effective than non-bypass procedures for psoriasis outcomes.
4. Patient Selection is Important: Factors such as age, weight loss potential, and family history may influence results.
5. Weight Loss Enhances Quality of Life: Significant reductions in DLQI scores suggest that MBS may improve overall well-being in addition to skin outcomes.

However, clinicians should note that MBS is not a psoriasis treatment per se. Surgical risks, long-term follow-up, and patient-specific factors must be carefully considered. MBS should only be pursued for standard indications related to obesity and metabolic health.

Limitations of Current Evidence

Despite promising findings, several limitations affect the interpretation of existing studies:

• Most studies were observational or case series with serious risk of bias.
• Sample sizes were small, particularly for non-bypass procedures.
• Outcome definitions and follow-up periods varied significantly.
• Meta-analysis was not possible due to heterogeneity.
• Mechanistic studies on GLP-1 and other hormonal pathways remain limited.

Consequently, while the evidence suggests a potential benefit of MBS for psoriasis, definitive conclusions cannot be drawn. Further large, prospective, controlled studies are needed to clarify the impact of surgery on psoriasis severity and to identify the underlying mechanisms.

Future Directions

Future research should focus on:

• Prospective Comparative Studies: Head-to-head trials comparing gastric bypass and sleeve gastrectomy for psoriasis outcomes.
• Standardized Outcome Measures: Consistent use of PASI, %ABSA, DLQI, and nail indices to allow better comparisons across studies.
• Mechanistic Investigations: Understanding how hormonal changes post-surgery affect psoriasis pathophysiology.
• Long-Term Follow-Up: Assessing whether improvements are sustained over years.
• Personalized Approaches: Identifying patient characteristics that predict favorable outcomes to guide surgical decision-making.

These studies will help clinicians provide more informed counseling and optimize management for patients with obesity and psoriasis.

Summary

Metabolic bariatric surgery is primarily indicated for obesity and metabolic disease management, yet evidence suggests it may also improve psoriasis outcomes. Key points from recent studies include:

• Significant reductions in PASI, %ABSA, and DLQI following surgery.
• Reduced treatment requirements, particularly systemic therapy.
• Gastric bypass procedures may offer superior benefits compared to non-bypass approaches.
• Patient characteristics, including age, baseline severity, and family history, can influence outcomes.

While the evidence is promising, it remains preliminary. MBS should not be considered a primary therapy for psoriasis, but it may provide an additional benefit for patients already meeting criteria for obesity surgery.

Key Takeaways for Patients and Clinicians

• Weight loss through MBS can positively affect psoriasis, likely by reducing systemic inflammation and altering hormonal pathways.
• Gastric bypass procedures may offer greater improvement than sleeve gastrectomy or gastric banding.
• Reduction in psoriasis treatment burden is possible after successful surgery.
• Individual patient factors should guide expectations and surgical planning.
• Further high-quality research is necessary to establish clear guidelines.

References

1. Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021;157(8):940-946.
2. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303-307.
3. De Brandt E, Hillary T. Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management. Psoriasis (Auckl). 2022;12:113-126.
4. Oon HH, Tan C, Aw DCW, et al. 2023 Guidelines on the Management of Psoriasis by the Dermatological Society of Singapore. Ann Acad Med Singap. 2024;53(9):562-577.
5. Kehagias D, Lampropoulos C, Pellen M, et al. Psoriasis outcomes following metabolic bariatric surgery - a systematic review of the literature. BMC Surg. 2026; https://doi.org/10.1186/s12893-026-03502-1.
6. Faurschou A, Zachariae C, Skov L, et al. Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? Med Hypotheses. 2011;77(6):1098-1101.
7. Paschou IA, Sali E, Paschou SA, et al. The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. J Eur Acad Dermatol Venereol. 2025.
8. Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes. 2015;39(8):1197-1202.

Disclaimer

This blog is for informational purposes only and should not replace professional medical advice. Metabolic bariatric surgery carries risks and is not a primary treatment for psoriasis. Patients should consult a qualified healthcare professional for individualized evaluation and recommendations.